# Daridorexant for Alzheimer Disease Prevention

> **NCT07213349** · PHASE2 · RECRUITING · sponsor: **Douglas Mental Health University Institute** · enrollment: 240 (estimated)

## Conditions studied

- Alzheimer Disease (AD)

## Interventions

- **DRUG:** Daridorexant 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07213349
- **Lead sponsor:** Douglas Mental Health University Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213349, "Daridorexant for Alzheimer Disease Prevention". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07213349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*